Cargando…
Circulating tumor DNA (ctDNA) in the era of personalized cancer therapy
The heterogeneity of tumor is considered as a major difficulty to victorious personalized cancer medicine. There is an extremeneed of consistent response evaluation for in vivo tumor heterogeneity anditscoupledconflict mechanisms. In this occasion researchers will be able to keep pace withpredictive...
Autores principales: | Khatami, Fatemeh, Tavangar, Seyed Mohammad |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6154523/ https://www.ncbi.nlm.nih.gov/pubmed/30288382 http://dx.doi.org/10.1007/s40200-018-0334-x |
Ejemplares similares
-
Liquid Biopsy-Analysis of Circulating Tumor DNA (ctDNA) in Bladder Cancer
por: Todenhöfer, Tilman, et al.
Publicado: (2018) -
Circulating Tumor BRAF Mutation and Personalized Thyroid Cancer Treatment
por: Khatami, Fatemeh, et al.
Publicado: (2017) -
Use of Circulating Tumour DNA (ctDNA) for Measurement of Therapy Predictive Biomarkers in Patients with Cancer
por: Duffy, Michael J., et al.
Publicado: (2022) -
The circulating tumor DNA (ctDNA) alteration level predicts therapeutic response in metastatic breast cancer: Novel prognostic indexes based on ctDNA
por: Liu, Binliang, et al.
Publicado: (2022) -
Clinical factors associated with circulating tumor DNA (ctDNA) in primary breast cancer
por: Zhou, Yidong, et al.
Publicado: (2019)